# Xeris Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xeris-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Chicago, US
- Website: www.xerispharma.com
- Total disclosed funding: $81M
- Latest round: Series C (Mar 8, 2018)
- Investors on record: 9

## About

Xeris Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical firm focused on innovative drug delivery solutions, particularly in endocrinology and neurology, enhancing patient accessibility and compliance with medication regimens.Founded in 2005, Xeris Pharmaceuticals, Inc. operates from Chicago, US, specializing in developing drug delivery systems. The company raised USD 86 mn in an IPO in June 2018 and further secured USD 27 mn in a Private Placement in March 2021. The CEO, Paul Edick, has led the company in addressing critical health issues with innovative solutions.Xeris Pharmaceuticals specializes in the development and commercialization of innovative drug delivery systems, particularly in the fields of endocrinology and neurology. The company's core product offerings include unique formulations that enable patients to administer medications conveniently and effectively, particularly using their proprietary technology that simplifies the delivery of complex biologics. Their flagship products address critical health issues, including diabetes management through a steady supply of insulin, and they aim to enhance patient compliance by reducing the burden of multiple daily injections. Xeris primarily serves healthcare providers, patients, and specialty pharmacies, with a focus on the U.S. market, while also exploring opportunities in Europe and other international markets for expansion.In the most recent fiscal year 2020, Xeris Pharmaceuticals reported a revenue of USD 20.15 mn and an EBITDA of USD -81.02 mn. Revenue is generated through direct sales to healthcare providers and partnerships with specialty pharmacies, reflecting the innovative delivery technology and significant health outcomes they provide.Xeris Pharmaceuticals plans to leverage the USD 27 mn raised in March 2021 for working capital and other corporate purposes, focusing on upcoming product launches and potential new markets. The company aims to expand its reach into European markets and enhance its product offerings that address chronic health conditions, capitalizing on its proprietary drug delivery technologies.

## Funding rounds

- Series C, Mar 8, 2018, $10M — Merieux Equity Partners, Wild Basin Investments
- Series C, May 17, 2017, $30M — Palmetto Partners, Bay City Capital, Merieux Equity Partners, Asahi Kasei Corporation, Redmile Group, Wild Basin Investments, Deerfield Management
- Series C, Jan 7, 2016, $41M — Redmile Group, Deerfield Management, McNair Group, Sabby Capital

## Investors

- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- McNair Group — Series C
- Sabby Capital (https://capitalatlas.ai/funds/sabby-capital) — Series C
- Palmetto Partners — Series C
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series C
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series C
- Asahi Kasei Corporation — Series C
- Wild Basin Investments (https://capitalatlas.ai/funds/wild-basin-investments) — Series C